Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Giuseppe Saglio, Dong-Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Clarisse Lobo, Ricardo Pasquini, Richard E Clark, Andreas Hochhaus, Timothy P Hughes, Neil Gallagher, Albert Hoenekopp, Mei Dong, Ariful Haque, Richard A Larson, Hagop M Kantarjian, ENESTnd Investigators, Ole Weis Bjerrum

    1448 Citations (Scopus)

    Abstract

    Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.
    Original languageEnglish
    JournalNew England Journal of Medicine
    Volume362
    Issue number24
    Pages (from-to)2251-9
    Number of pages9
    ISSN0028-4793
    DOIs
    Publication statusPublished - 17 Jun 2010

    Fingerprint

    Dive into the research topics of 'Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia'. Together they form a unique fingerprint.

    Cite this